Abstract
156P Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have